ライブ

BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drug Endpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd BioWorldFirst cruise ship hantavirus genome points to zoonotic spillover BioWorldBiggest gainers and losers for May 4-8, 2026 Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan PLoS BiologyThe problem with one-size-fits-all medicine: Biological sex and the aging immune system PLoS BiologyUSP39 promotes antiviral defense through post-transcriptional control of RIG-I and stabilization of STING BioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Clinical OMICs 2026年5月11日

Brain-Controlled Hearing Aid Singles Out Voices in a Crowd

For the first time, a brain-controlled hearing aid allowed users to amplify the conversation they are focusing on while reducing other voices. The post Brain-Co...

For the first time, a brain-controlled hearing aid allowed users to amplify the conversation they are focusing on while reducing other voices. The post Brain-Controlled Hearing Aid Singles Out Voices in a Crowd appeared first on Inside Precision Medicine .